SCOHIA PHARMA

Executive Summary

Scohia Pharma is a Japanese specialty bioventure company founded in 2020, focused on developing small molecule therapeutics for lifestyle-related diseases, including metabolic, cardiovascular, renal, and endocrine disorders. The company leverages novel mechanisms of action and emphasizes minimizing development risk through backup compounds and strategic partnerships. With a diversified early-stage pipeline, Scohia aims to address significant unmet needs in chronic diseases. Its approach combines innovative science with a disciplined risk management strategy, positioning it as a potential player in the high-value metabolic and cardiovascular therapeutic markets. As a private, Phase 1-stage company, Scohia has yet to disclose detailed pipeline data, but its focus on lifestyle diseases aligns with growing global health trends. The company's success hinges on advancing its lead candidates through clinical trials and securing partnerships to share development costs and commercial reach. Key risks include the inherent uncertainty of early-stage drug development, competition from larger pharmaceutical companies, and limited visibility into its financial runway. However, its strategic use of backup compounds and partnerships may mitigate some development risks. Overall, Scohia represents an early-stage opportunity with a promising therapeutic focus, but requires careful monitoring of clinical progress and partnership activities.

Upcoming Catalysts (preview)

• Q4 2026Completion of Phase 1 trial for lead metabolic candidate60% success
• Q2 2027Announcement of strategic partnership for co-development50% success
• Q3 2026Preclinical data release for backup compound in cardiovascular indication70% success